Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of CFTR modulators in special populations, part 3: Solid organ transplant.

Pediatric pulmonology - 1 Dec 2023

Kadouh Nour K, Elijah Joseph, Fitzgerald Linda J, Phan Hanna

Abstract excerpt

BACKGROUND: Solid organ transplant (SOT) recipients with cystic fibrosis (CF) may benefit from the pulmonary and extrapulmonary benefits associated with CF transmembrane conductance regulator modulators. Nevertheless, evolution of modulator safety and efficacy data prompts consideration. METHODS: The search terms "transplant" AND "ivacaftor"(IVA) OR "lumacaftor"(LUM) OR "tezacaftor" (TEZ) OR "elexacaftor" (ELX)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Organ Transplantation

Share to Tacrolimus

Source

Identifiers

PMID: 37067449
DOI: 10.1002/ppul.26396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of CFTR modulators in special populations, part 3: Solid organ transplant.PMID 37067449Read ↗

Use of CFTR modulators in special populations, part 2: Severe lung disease.Semantic proximity Read ↗

The New and Advanced Cystic fibrosis transmembrane conductance regulators Modulators in Children with Cystic Fibrosis: A Narrative Review on Long-Term Outcomes, Recent Advances, and Comparative Insights.Semantic proximity Read ↗

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in FranceSemantic proximity Read ↗

Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.Semantic proximity Read ↗

Cystic Fibrosis Modulator Therapies.Semantic proximity Read ↗

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.Semantic proximity Read ↗

Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.Semantic proximity Read ↗

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.Semantic proximity Read ↗

Review of CFTR modulators 2020.Semantic proximity Read ↗

A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.